1. Scrip
  2. >>Focus On Asia
  3. >>India

Piramal settles desflurane litigation with Baxter, set to begin US manufacture in 2012

 
• By Anju Ghangurde

Piramal Critical Care, part of India's Piramal group, can manufacture desflurane, a generic version of Baxter's Suprane inhaled anaesthetic agent, in the US next year as part of a patent litigation settlement for the product.

Piramal Critical Care, part of India's Piramal group, can manufacture desflurane, a generic version of Baxter's Suprane inhaled anaesthetic agent, in the US next year as part of a patent litigation settlement for the product.

The US Court for the District of Delaware has dismissed the infringement suit between the two firms following the agreement.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.